CRISPR/Cas9 technology generated to C to T change at position c.2714 resulting in a proline to leucine substitution at amino acid 905 (p.P905L). This is equivalent to the p.P924L pathogenic variant found in two patients with epilepsy of infancy with migrating focal seizures (known as developmental and epileptic encephalopathy 14).